Viking Therapeutics, Inc. (VKTX) Stock Forecast 2026: P10, P50 & P90 — Probabli.AI
Timestamped VKTX stock forecast with 1-year P10, P50, and P90 price estimates, scenario probabilities, definitions, sources, and limitations.
Direct answer: Viking Therapeutics demonstrates high potential in the biopharmaceutical sector, particularly through its flagship VK2809, with strong advances in clinical trials. Analyst sentiment, significant pipeline opportunities, and projected milestones make this a compelling investment, albeit with substantial competitive and financial risks. Mixed near-term developments are outweighed by long-term growth prospects. The saved 1-year distribution is P10 $26, P50 $45, and P90 $100.
Last analyzed · Model: gpt-4o
Viking Therapeutics, Inc. Forecast data
| Estimate | 1-year price | Meaning |
|---|
| P10 | $26 | Pessimistic plausible scenario |
| P50 | $45 | Median scenario |
| P90 | $100 | Optimistic plausible scenario |
What the numbers mean
P10, P50, and P90 are model-generated scenario estimates: roughly a pessimistic plausible outcome, a median outcome, and an optimistic plausible outcome. They are not calibrated confidence intervals.
Supporting analysis
Viking Therapeutics has strong potential backed by positive drug development updates, analyst confidence with highly elevated price targets, and meaningful strides in advancing VK2809. However, it faces execution risks, competitive pressure in the NASH market, and negative EPS surprises. Sentiment is tilted bullish overall.
Sources and limitations
Market and company inputs are primarily sourced through Yahoo Finance and public financial-data interfaces. This page reports a saved AI-generated scenario analysis as of the timestamp above; it is not live data, audited probability, financial advice, or a guaranteed return.
Frequently asked questions
When was this VKTX analysis generated?
March 8, 2026.
Is this a guaranteed VKTX prediction?
No. It is a model-generated scenario assessment with material uncertainty.
View the full VKTX stock analysis · VKTX sentiment · Methodology · Accuracy & validation
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.